NCT04756323View on ClinicalTrials.gov

A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)

PHASE2UnknownINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

February 28, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

medium dosage inactivated SARS-CoV-2 vaccine

medium dosage

BIOLOGICAL

high dosage inactivated SARS-CoV-2 vaccine

high dosage

BIOLOGICAL

Placebo

placebo

Trial Locations (1)

210000

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

Sponsors
All Listed Sponsors
collaborator

Shenzhen Kangtai Biological Products Co., LTD

INDUSTRY

collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

lead

Beijing Minhai Biotechnology Co., Ltd

INDUSTRY